Egg phospholipids exert an inhibitory effect on intestinal cholesterol absorption in mice

Yoojin Lee1, Catherine Y. Han1, Minkyung Bae1, Young-Ki Park1 and Ji-Young Lee1,2§

1Department of Nutritional Sciences, University of Connecticut, Storrs, Connecticut 06269, USA
2Department of Food and Nutrition, Kyung Hee University, Seoul 02447, South Korea

BACKGROUND/OBJECTIVES: Consumption of cholesterol-rich foods, such as eggs, has a minimal effect on circulating cholesterol levels in healthy humans. To gain insight, we investigated whether phospholipids rich in eggs (EPL) interfere with intestinal cholesterol absorption in vivo.

MATERIALS/METHODS: To investigate the acute effect of EPL on intestinal cholesterol absorption, male C57BL/6J mice were orally administered with 6, 11, or 19 mg of EPL for three days. We also tested the effect of chronic EPL consumption on cholesterol metabolism in the small intestine and the liver in mice with diet-induced hypercholesterolemia. Male C57BL/6J mice were fed a high fat/high cholesterol (HF/HC; 35% fat, 0.25% cholesterol, w/w) diet for 4 weeks to induce hypercholesterolemia, and subsequently the mice were either fed 0, 0.4 or 0.8% (w/w) of EPL for 6 weeks.

RESULTS: Intestinal cholesterol absorption was significantly decreased by the highest dose of acute EPL administration compared to control. Chronic EPL supplementation did not significantly alter intestinal cholesterol absorption nor plasma levels of total cholesterol and low-density lipoprotein cholesterol. In the small intestine and the liver, EPL supplementation minimally altered the expression of genes which regulate cellular cholesterol levels.

CONCLUSION: Although chronic EPL consumption was not able to counteract hypercholesterolemia in HF/HC-fed mice, acute EPL administration decreased intestinal cholesterol absorption. This study provides in vivo evidence that acute administration of PLs in eggs prevent cholesterol absorption in the intestine, suggesting a mechanism for a minimal effect of egg consumption on circulating cholesterol levels.

INTRODUCTION

Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for ~31% of global deaths in 2012 according to World Health Organization [1]. Atherosclerosis, a condition characterized by the accumulation of lipid-laden plaques in the blood vessel, is one of the major contributors to the pathogenesis of CVD [2]. High concentrations of serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) facilitate atherosclerosis development [3]. The consumption of foods containing high amount of cholesterol, such as eggs and animal products, was limited to maintain normal serum TC and LDL-C concentrations until recently. National Dietary Guidelines of 2015-2020 eliminated the recommendation that limits daily dietary cholesterol consumption to 300 mg due to a lack of evidence supporting a positive relationship between dietary cholesterol intake and hypercholesterolemia in humans [4-7].

While studies have shown a positive association of egg intake with CVD risk in humans with type 2 diabetes mellitus or coronary heart disease [8-10], egg consumption does not raise plasma TC concentrations in healthy humans [11,12] although the underlying mechanisms remain elusive. Studies have suggested that constituents of eggs, such as phospholipids, ovomucin, and caseins, may prevent an increase in plasma TC concentrations after consuming eggs [13-15]. One compelling mechanism is related to high phospholipid (PL) contents in eggs. Eggs are rich in PL, accounting for approximately 10-40% of daily PL consumption in the U.S. [2]. Interestingly, it has been shown that PL can reduce intestinal cholesterol absorption in animals and humans [16-19]. Therefore, it is presumable that egg PL (EPL) may inhibit intestinal absorption of the cholesterol present in eggs. In support of this possibility, duodenal infusion of egg phosphatidylcholine, a major PL species in eggs, inhibited cholesterol absorption in rats as demonstrated by lower level of absorbed cholesterol in the lymph compared to control rats [20]. However, there is a lack of in vivo evidence that demonstrates a possible inhibitory effect of EPL on...
intestinal cholesterol absorption. Therefore, in this study, we sought to determine whether acute EPL administration or chronic consumption of EPL could alter intestinal cholesterol absorption as well as cholesterol metabolism in mice.

**MATERIALS AND METHODS**

**Animal feeding and care**  
Acute administration of EPL  
Male C57BL/6J mice (The Jackson Laboratory, Bar Harber, ME, USA) on a regular chow diet were gavaged with increasing daily dosages, i.e., 6, 11, and 19 mg/mouse (n = 5, 5, and 8, respectively), of EPL for 3 consecutive days. EPL (powdered L-α-phosphatidylcholine) was purchased from Avanti Polar Lipids (Alabaster, AL, USA). Fecal samples were collected 24 h after the last EPL gavage to determine intestinal cholesterol absorption as described below.

Chronic consumption of EPL  
To investigate the effect of chronic consumption of EPL on cholesterol metabolism, male C57BL/6J mice at age of 11 weeks were fed a modified AIN-93M high fat/high cholesterol diet (HF/HC; 35% fat, 0.25% cholesterol, w/w) for 4 weeks to induce hypercholesterolemia. Subsequently, mice were fed a HF/HC control diet or a HF/HC supplemented with 0.4% or 0.8% EPL (n = 8 and 10, respectively) by weight (HF/HC-EPL) for 6 weeks. Detailed diet composition is described in Table 1. Mouse body weights and food consumption were recorded weekly. Intestinal cholesterol absorption was determined 5 weeks after mice were fed the experimental diets as described below. After 6 weeks on the experimental diets, mice were anesthetized with ketamine-HCl (110 mg/kg)/xylazine (10 mg/kg) (Henry Schein Animal Health, Dublin, OH, USA) after 8 h fasting, and then euthanized by cardiac puncture and subsequent cervical dislocation. Mouse blood samples were collected 24 h after temperature for 30 min, and then centrifuged at 1,500 x g at 4°C for 15 min to remove red blood cells. Liver and small intestine samples were collected, weighed, snap-frozen, and stored at -80°C until use.

EPL dosages were determined based on body surface normalization to a 70 kg human individual [21]. EPL dosages of 6, 11, and 19 mg/mouse for oral gavage are equivalent to 0.8, 1.5, and 2.5 eggs in humans. Dietary supplementations of EPL at 0.4% and 0.8% (w/w) are equivalent to daily consumption of ~1.5 eggs and ~3 eggs, respectively, in humans. All mice were maintained under the 12 h light/12 h dark cycle with free access to food and water. All procedures were approved by the Institutional Animal Care and Use Committee of the University of Connecticut (protocol # A13-026).

**Intestinal cholesterol absorption rate analysis**  
Acute administration of EPL  
For the evaluation of the acute effect of EPL on intestinal cholesterol absorption, mice were gavaged daily with 30 μL of vegetable oil only or of one of 3 EPL doses (6, 11, or 19 mg per mouse) for 3 days as previously described [22]. To determine intestinal cholesterol absorption rate, we used [14C]-labeled cholesterol with 3H-labeled sitosterol which serves as a nonabsorbable control. On the first day, mice were administered with 0.1 μCi of [14C]cholesterol and 0.14 μCi of [3H]sitosterol (American Radiolabeled Chemicals, St. Louis, MO, USA) 30 min after EPL gavage. Fecal samples were collected 24 h after the last day of EPL gavage. Fecal lipids were extracted using Folch method as previously described [23,24], and the ratio of [14C]cholesterol to [3H]sitosterol in fecal lipids were calculated to determine intestinal cholesterol absorption rates.

Chronic consumption of EPL  
For the chronic study, mice fed with either a HF/HC control or HF/HC-EPL were gavaged with 0.09 μCi of [14C]cholesterol and 0.13 μCi of [3H]sitosterol for 2 consecutive days after 5 weeks of experimental diets and fecal samples were collected 5 days after the first gavage of [14C]cholesterol and [3H]sitosterol. Fractional intestinal cholesterol absorption was determined by the dual fecal isotope method used in acute study.

**Blood chemistry**  
Circulating concentrations of TC and triglyceride (TG) were enzymatically measured using L-Type TG M kit (Wako, Richmond, VA, USA) and Cholesterol reagent set (Pointe Scientific, Canton, MI, USA), respectively, as we previously described [25]. Plasma concentrations of high-density lipoprotein cholesterol (HDL-C) were measured using the Cholesterol reagent set after precipitating apoB containing lipoproteins using HDL cholesterol precipitating reagent set (Pointe Scientific, Canton, MI, USA).

**Gene expression analysis using reverse transcription quantitative real time PCR (RT-qPCR)**  
Total RNA from liver and intestine was extracted as previously described [25]. The expression of genes involved in cholesterol transport, synthesis, and uptake was determined by RT-qPCR as we previously described using the SYBR Green procedure.

### Table 1. Diet composition of a HF/HC control diet or a HF/HC diet containing EPL

|            | HF/HC 1 | HF/HC 0.4% EPL 2 | HF/HC 0.8% EPL 2 |
|------------|---------|------------------|------------------|
| Comstarch  | 164.0   | 162.0            | 160.0            |
| Dextrinized Cornstarch | 100.0 | 100.0            | 100.0            |
| Sucrose    | 140.0   | 140.0            | 140.0            |
| Casein     | 140.0   | 140.0            | 140.0            |
| L-Cystine  | 1.8     | 1.8              | 1.8              |
| Lard       | 310.0   | 308.0            | 306.0            |
| Soybean oil| 40.0    | 40.0             | 40.0             |
| Insoluble fiber | 50.0 | 50.0             | 50.0             |
| AIN-93 mineral mix | 40.0 | 40.0             | 40.0             |
| AIN-93 vitamin mix | 10.0 | 10.0             | 10.0             |
| Choline bitartrate | 2.0 | 2.0              | 2.0              |
| Cholesterol | 2.5 | 2.5              | 2.5              |
| t-Butylhydroquinone | 0.008 | 0.008            | 0.008            |
| Egg Phospholipid | 0.0 | 4.0              | 8.0              |

*1*HF/HC control diet contains 35% fat and 0.25% cholesterol by weight,  
*2*Egg phospholipid supplementation levels by weight,
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was used as a reference gene for data normalization.

**Statistical Analysis**

Unpaired t-test was performed by GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA) to identify statistically significant differences between groups. $P < 0.05$ was considered significant. Data are expressed as mean ± standard error of the mean (SEM).

**RESULTS**

**Body and liver weights, and blood lipids in HF/HC diet-fed mice**

Supplementation of 0.4% or 0.8% EPL diet for 6 weeks did not significantly alter body and liver weights of mice compared with HF/HC control mice (data not shown). EPL consumption did not alter circulating TC, HDL-C and TG concentrations compared to those of the control (Table 2).

**Effect of acute and chronic consumption of EPL on intestinal cholesterol absorption**

There were no significant differences in intestinal cholesterol absorption when mice acutely consumed EPL at dosages of 6 or 11 mg compared to control (Table 3). However, 19 mg of EPL administration significantly decreased intestinal cholesterol absorption compared to control ($P = 0.01$). Consumption of 0.4% EPL for 6 weeks, however, did not significantly alter intestinal cholesterol absorption in hypercholesterolemic mice.

---

**Table 2. Plasma/Serum triglyceride, total cholesterol, and HDL cholesterol levels of hypercholesterolemic C57BL/6J mice fed a HF/HC control diet or a HF/HC diet supplemented with 0.4% (w/w) or 0.8% (w/w) EPL for 6 weeks**

| EPL Concentration | Week 4 | Week 10 | P-value |
|-------------------|--------|---------|---------|
| **Plasma/Serum Triglyceride (mg/dL)** | | | |
| 0.4% EPL | 34.7 ± 2.03 | 39.0 ± 1.36 | 0.098 |
| 0.8% EPL | 28.4 ± 1.59 | 22.6 ± 2.23* | 0.048 |
| **Plasma/Serum Total Cholesterol (mg/dL)** | | | |
| 0.4% EPL | 158.4 ± 8.82 | 156.6 ± 4.64 | 0.857 |
| 0.8% EPL | 124.7 ± 2.59 | 104.6 ± 7.46* | 0.046 |
| **Plasma/Serum HDL Cholesterol (mg/dL)** | | | |
| 0.4% EPL | 86.8 ± 7.10 | 87.2 ± 6.30 | 0.966 |
| 0.8% EPL | 94.5 ± 6.92 | 100.5 ± 8.22 | 0.587 |

---

**Table 3. Fractional intestinal cholesterol absorption of C57BL/6J mice fed a regular chow diet and gavaged with 6, 11, or 19 mg of EPL per mouse**

| EPL Concentration | Dosage of 6 mg/day/mouse | Dosage of 11 mg/day/mouse | Dosage of 19 mg/day/mouse | P-value |
|-------------------|--------------------------|--------------------------|--------------------------|---------|
| **Intestinal cholesterol absorption (%)** | | | | |
| 0.4% EPL | 57.9 ± 2.85 | 56.8 ± 1.16 | 0.73 |
| **Intestinal cholesterol absorption (%)** | | | | |
| 0.8% EPL | 57.9 ± 2.85 | 55.9 ± 1.09 | 0.48 |
| **Intestinal cholesterol absorption (%)** | | | | |
| 1% EPL | 58.3 ± 1.29 | 53.4 ± 1.14* | 0.01 |

---

1) Data are expressed as mean ± SEM

* $P < 0.05$ compared to control.

EPL: egg phospholipid; HDL, high-density lipoprotein.
Table 4. Gene expression analysis in the liver and the small intestine of hypercholesterolemic C57BL/6J mice fed HF/HC control diet or HF/HC supplemented with 0.4% (w/w) or 0.8% (w/w) EPL for 6 weeks.\(^1\)

| Gene    | Control      | EPL           | P-value |
|---------|--------------|---------------|---------|
| Liver   |              |               |         |
| 0.4% EPL|              |               |         |
| Nr1h3   | 1.0 ± 0.16   | 0.8 ± 0.08*   | 0.01    |
| Abca1   | 1.0 ± 0.05   | 0.8 ± 0.06*   | 0.03    |
| Abcg5   | 1.0 ± 0.10   | 0.8 ± 0.05    | 0.06    |
| Sreb2   | 1.0 ± 0.07   | 0.8 ± 0.06*   | 0.01    |
| Hmgcr   | 1.0 ± 0.09   | 1.0 ± 0.08    | 0.68    |
| Ldlr    | 1.0 ± 0.09   | 0.8 ± 0.07    | 0.23    |
| Scarb1  | 1.0 ± 0.08   | 0.9 ± 0.06    | 0.14    |
| 0.8% EPL|              |               |         |
| Nr1h3   | 1.1 ± 0.17   | 0.97 ± 0.12   | 0.25    |
| Abca1   | 1.0 ± 0.09   | 1.2 ± 0.11    | 0.30    |
| Sreb2   | 1.2 ± 0.21   | 1.5 ± 0.24    | 0.25    |
| Hmgcr   | 1.1 ± 0.12   | 1.0 ± 0.10    | 0.65    |
| Ldlr    | 1.0 ± 0.06   | 1.0 ± 0.07    | 0.57    |
| Small intestine | 0.4% EPL |              |         |
| Npc1l1  | 1.1 ± 0.19   | 1.0 ± 0.11    | 0.68    |
| Hmgcr   | 1.1 ± 0.22   | 1.0 ± 0.26    | 0.62    |
| Ldlr    | 1.2 ± 0.24   | 0.7 ± 0.11    | 0.08    |
| Abca1   | 1.1 ± 0.16   | 2.5 ± 0.83    | 0.14    |
| Abcg5   | 1.1 ± 0.22   | 1.0 ± 0.21    | 0.71    |
| 0.8% EPL|              |               |         |
| Npc1l1  | 1.0 ± 0.07   | 0.3 ± 0.13*   | 0.0002  |
| Hmgcr   | 3.4 ± 1.8    | 3.4 ± 0.43    | 0.99    |
| Ldlr    | 1.1 ± 0.14   | 1.2 ± 0.20    | 0.68    |
| Abca1   | 1.1 ± 0.16   | 0.7 ± 0.11    | 0.07    |
| Abcg5   | 1.0 ± 0.10   | 0.8 ± 0.06    | 0.06    |

\(^1\) Data are expressed as relative expression to HF/HC control and represent mean ± SEM.
* P < 0.05 compared to control.
EPL: egg phospholipid

Fig. 1. The effect of EPL on hepatic SREBP-2, LDLR, and HMGCR protein levels in mice with hypercholesterolemia. Mice were fed with a HF/HC diet for 4 weeks to induce hypercholesterolemia, and then subsequently fed with a HF/HC control or 0.8% EPL (w/w) supplemented HF/HC diet for 6 weeks. (A) Western blot analysis of cholesterol homeostasis related proteins in mouse liver fed with a HF/HC control group or a HF/HC supplemented with 0.8% EPL (w/w), n=10. (B) Quantitative analysis of Western blot analysis. Data are shown as means ± SEM, * P<0.05.

Effect of chronic EPL consumption on intestinal and hepatic gene expression

We determined whether chronic EPL consumption in a hypercholesterolemic condition could alter the expression of genes involved in cholesterol transport, synthesis, and uptake in the liver. mRNA levels of nuclear receptor subfamily 1 group H member 3 (Nr1h3), which functions as an oxysterol sensor, as well as its target gene, ATP-binding cassette transporter A1...
compared to the control (Table 4). Also, hepatic mRNA abundance of sterol regulatory element-binding factor 2 (Srebf2) was decreased by 0.4% EPL supplementation, while its downstream genes, such as HMG-CoA reductase (Hmgcr) and LDL receptor (Ldlr), were not significantly different between control and 0.4% EPL-fed mice. EPL supplementation at a dose of 0.4% did not significantly change mRNA of ATP-binding cassette transporter GS (Abcg5), sterol regulatory element-binding factor 1c, and scavenger receptor class B type 1 (Scarb1) (data not shown).

Mice fed 0.8% EPL supplementation did not show any significant changes in their hepatic mRNA levels of Nr1h3, Abca1, Srebf2, Hmgcr, and Ldlr compared with control. However, hepatic SREBP-2 and LDLR proteins were decreased in 0.8% EPL group compared with control although their respective mRNA levels were not different (Fig. 1). Hepatic HMGCR protein levels were not altered by 0.8% EPL consumption.

In the small intestine, mRNA abundance of Niemann-Pick C1-Like 1 (Npc1l1), a major cholesterol transporter, was significantly decreased by 0.8%, but not 0.4% EPL consumption. However, any of EPL doses did not significantly alter mRNA levels of Hmgcr, Ldlr, Abca1, and Abcg5.

**DISCUSSION**

High plasma TC and LDL-C concentrations are the primary risk factors of CVD [26]. Therefore, dietary cholesterol was historically viewed as a dietary component that increased CVD risk [27], and the American Heart Association set a dietary recommendation to limit dietary cholesterol consumption to less than 300 mg/day in 1968 [28]. In the 2015 dietary guideline, the recommendation was eliminated based on mounting evidence that dietary cholesterol does not increase incidents of heart diseases [5,27,29,30]. However, the underlying mechanisms for the observation have not been clearly elucidated. Inhibition of intestinal cholesterol absorption largely affects plasma TC concentrations [31], and dietary PL from various sources, including egg yolk, soybeans, and milk, have been suggested to inhibit intestinal cholesterol absorption [16,20]. Therefore, we sought to determine whether acute or chronic consumption of EPL, accounting for ~28% of total lipids in eggs by weight [2], may inhibit intestinal cholesterol absorption. In the present study, we found that acute EPL administration at a dosage equivalent to 2.5 eggs in humans significantly reduced intestinal cholesterol absorption in mice while chronic consumption of EPL equivalent to 1.5 eggs in humans was not able to alter intestinal cholesterol absorption in hypercholesterolemic mice. This inhibitory action of EPL on intestinal cholesterol absorption explains, at least in part, the observations in several studies which show that egg consumption did not increase plasma TC concentrations in healthy humans despite high daily intake of dietary cholesterol from eggs [11,12].

Our study found that acute oral administration of 19 mg EPL significantly reduced intestinal cholesterol absorption in mice. This finding provides in vivo evidence, which supports the previous report that duodenal infusion of lipid emulsion containing egg phosphatidylcholine, a major PL species in eggs, reduced cholesterol levels in the collected lymph compared to control rats [20]. Although how EPL inhibits intestinal cholesterol absorption has not been clearly demonstrated, the inhibitory action of EPL may be related to its role in the modulation of interaction between micelles and enzymes/receptors involved in cholesterol absorption. We assume that it is possible that increased micellar EPL may inhibit binding of micelles to SR-B1, a cholesterol membrane transporter in the small intestine [32], thereby decreasing intestinal cholesterol absorption. In fact, Goncalves et al. [33] demonstrated that the composition of micelles affects an interaction between micelles and SR-B1. Using mixed micelles prepared with different concentrations of phosphatidylcholine, they reported a linear decrease in the binding capacity of micelles to SR-B1 with increasing concentrations of phosphatidylcholine. However, considering NPC1L1, but not SR-B1, is the major cholesterol transporter in the intestine [34], and cell-based as well as in vivo evidence is lacking to support the action of PL, it is not clear how much this action of PL in lowering the binding of micelles to SR-B1 can contribute to overall intestinal cholesterol absorption. Further studies are necessary to determine the role of EPL on the composition of micelles and their interaction with intestinal cholesterol transporters, i.e., NPC1L1 and SR-B1.

Another possible mechanism for the inhibitory action of EPL on cholesterol absorption is that EPL may impede the hydrolysis of micellar PLs by phospholipase A2 (PLA2), thus inhibiting the uptake of micellar cholesterol by the enterocyte. Previous studies have demonstrated that PLA2 is crucial for cholesterol uptake into the enterocyte by decreasing the micellar PL contents. Studies have shown that FPL 67047XX, a PLA2 inhibitor, decreased cholesterol absorption in vitro and in vivo. In Caco-2 cells, the PLA2 inhibitor abolished a PLA2-dependent increase in cellular cholesterol uptake from micelles [35]. Similarly, duodenal infusion of lipid emulsion containing the PLA2 inhibitor significantly reduced cholesterol absorption in rats [36]. Therefore, it is presumed that increased micellar PL contents due to EPL consumption may inhibit intestinal cholesterol absorption via impendence of PLA2 action. Further study is needed to determine whether the enrichment of micelles with EPL elicits inhibitory action against the binding capacity of micelles to SR-B1, and PLA2-dependent cellular uptake of cholesterol to inhibit intestinal cholesterol absorption.

In our study, although acute administration of high EPL dose significantly inhibited intestinal cholesterol absorption in mice, EPL consumption for 6 weeks did not alter intestinal cholesterol absorption in hypercholesterolemic mice. In addition, EPL supplementation was not able to counteract HF/HC diet-induced increases in plasma TC, HDL-C, and TG concentrations. In the small intestine, 0.8% EPL supplementation reduced Npc1l1 mRNA expression in hypercholesterolemic mice, however, the expression of other genes sensitive to cellular cholesterol levels, such as Hmgcr, Ldlr, Abca1, and Abcg5, in the small intestine were not altered by EPL. In the liver, mRNA abundance of Nr1h3, Abca1, and Srebf2 decreased by 0.4% EPL supplementation, and SREBP-2 and LDLR protein levels were decreased in 0.8% EPL-fed mice. However, the changes in cholesterol metabolism-related mRNA and protein levels did not alter plasma cholesterol levels in hypercholesterolemia-induced mice, suggesting that the inhibitory role of EPL against intestinal absorption has not been clearly demonstrated.
cholesterol absorption in mice fed a normal chow was not achievable in hypercholesterolemia-induced mice. The discrepancy of the role of EPL in the regulation of intestinal cholesterol absorption between acute and chronic studies might be due to cholesterol and fat contents used in the experimental diet. High contents of cholesterol and fat in the experimental diet used for the chronic study might not be counteracted by the levels of EPL supplementation. This result suggests that EPL does not counteract hypercholesterolemia in diet-induced obesity, which is consistent with the evidence that reports a positive correlation with the egg consumption and CVD risk in type 2 diabetic patients [8,9]. However, it would be worthwhile to conduct a study using different levels of cholesterol and fats in experimental diets to investigate the effect of chronic consumption of EPL on intestinal cholesterol absorption.

In conclusion, this study demonstrates that acute oral administration of EPL inhibits intestinal cholesterol absorption in mice fed a normal chow, while chronic EPL consumption with a HF/HC diet did not alter plasma TC levels and intestinal cholesterol absorption in hypercholesterolemic mice. Several mechanisms are suggested to demonstrate the inhibitory action of EPL on cholesterol absorption in the intestine, however, more research is needed to elucidate the possible mechanisms by which EPL inhibits intestinal cholesterol absorption at the whole body and cell levels. Despite the beneficial effect of EPL in cholesterol absorption, concerns of EPL consumption remain, as EPL provides a substrate for trimethylamine N-Oxide (TMAO), a CVD marker [2]. Miller et al. [37] have demonstrated that egg consumption increases the postprandial level of plasma TMAO in humans. Therefore, further studies are warranted to investigate the effect of chronic EPL consumption on TMAO formation and its contribution to CVD.

Nonetheless, our study provides in vivo evidence that EPL administration inhibits intestinal cholesterol absorption. Importantly, this observation demonstrates for the first time to our knowledge that consumption of PL in eggs prevents intestinal cholesterol absorption, which provides an explanation why the consumption of eggs rich in cholesterol does not exert hypercholesterolemic effects in most of the human population.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

Y. Lee, C. Y. Han, M. Bae and Y. Park carried out experiments and performed data analysis; Y. Lee, C. Y. Han, and J. Lee wrote the manuscript; and J. Lee designed the study and led the study.

ORCID

Yoojin Lee: https://orcid.org/0000-0003-2475-5857
Catherine Y. Han: https://orcid.org/0000-0003-0105-6877
Minkyung Bae: https://orcid.org/0000-0002-3289-5166
Young-Ki Park: https://orcid.org/0000-0003-3503-5847
Ji-Young Lee: https://orcid.org/0000-0002-7945-793x

REFERENCES

1. World Health Organization. World Health Statistics 2016: Monitoring Health for the SDGs Sustainable Development Goals: World Health Organization; 2016.
2. Blesso C. Egg Phospholipids and Cardiovascular Health. Nutrients 2015;7:2731.
3. Johnston TP, Korolenko TA, Pirro M, Sahebkar A. Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management. Pharmacological Research 2017;120:219-25.
4. U.S. Department of Health and Human Services USDa. 2015-2020 Dietary Guidelines for Americans 2015 Available from: https://health.gov/dietaryguidelines/2015/guidelines/.
5. McNamara DJ. Dietary cholesterol, heart disease risk and cognitive dissonance. Proceedings of the Nutrition Society 2014;73:161-66.
6. P2Namara D. Cholesterol intake and plasma cholesterol: an update. Journal of the American College of Nutrition 1997;16:530-34.
7. Fernandez ML. Rethinking dietary cholesterol. Current Opinion in Clinical Nutrition & Metabolic Care 2012;15:117-21.
8. Griffin BA. Eggs: good or bad? Proceedings of the Nutrition Society 2016;75:259-64.
9. Spence JD, Jenkins DJ, Davignon J. Dietary cholesterol and egg yolks: not for patients at risk of vascular disease. Canadian Journal of Cardiology 2010;26:e336-e39.
10. Shin JY, Xun P, Nakamura Y, He K. Egg consumption in relation to risk of cardiovascular disease and diabetes: a systematic review and meta-analysis. The American Journal of Clinical Nutrition 2013;98:146-59.
11. DiMarco DM, Missimer A, Murillo AG, Lemos BS, Malycheva OV, Caudill MA, Blesso CN, Fernandez ML. Intake of up to 3 Eggs/Day Increases HDL Cholesterol and Plasma Choline While Plasma Trimethylamine-N-oxide is Unchanged in a Healthy Population. Lipids 2017;52:255-63.
12. Kishimoto Y, Taguchi C, Suzuki-Sugihara N, Saita E, Usuda M, Wang W, Masuda Y, Kondo K. The Effect of the Consumption of Egg on Serum Lipids and Antioxidant Status in Healthy Subjects. Journal of Nutritional Science and Vitaminology 2016;62:361-65.
13. Nagaoaka S, Masaoka M, Zhang Q, Hasegawa M, Watanabe K. Egg ovomucin attenuates hypercholesterolemia in rats and inhibits cholesterol absorption in Caco-2 cells. Lipids 2002;37:267-72.
14. Okey R, Pencharz R, Lepkovsky S, Vernon ER, Jerome D, Marquette M. Dietary constituents which may influence the use of food cholesterol. 1. Eggs: biotin and avidin. Journal of Nutrition 1951;44:83-99.
15. Matsuoka R, Kimura M, Muto A, Masuda Y, Sato M, Imaizumi K. Mechanism for the Cholesterol-Lowering Action of Egg White Protein in Rats. Bioscience, Biotechnology, and Biochemistry 2008;72:1506-12.
16. Cohn JS, Wat E, Kamili A, Tandy S. Dietary phospholipids, hepatic lipid metabolism and cardiovascular disease Current Opinion in Lipidology 2008;19:257-62.
17. Eckhardt ER, Wang DQH, Donovan JM, Carey MC. Dietary sphingomyelin suppresses intestinal cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers. Gastroenterology 2002;122:948-56.
18. Noh SK, Koo SI. Milk Sphingomyelin is More Effective than Egg Sphingomyelin in Inhibiting Intestinal Absorption of Cholesterol
and Fat in Rats. The Journal of Nutrition 2004;134:2611-16.
19. Beil FU, Grundy S. Studies on plasma lipoproteins during absorption of exogenenous lecithin in man. Journal of Lipid Research 1980;21:525-36.
20. Jiang Y, Noh SK, Koo SI. Egg Phosphatidylcholine Decreases the Lymphatic Absorption of Cholesterol in Rats. The Journal of Nutrition 2001;131:2358-63.
21. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. The FASEB Journal 2008;22:659-61.
22. Xie C, Zhou Z-S, Li N, Bian Y, Wang Y-J, Wang L-J, Li B-L, Song B-L. Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine. Journal of Lipid Research 2012;792.
23. Rasmussen HE, Blobaum KR, Jesch ED, Ku CS, Park Y-K, Lu F, Carr TP, Lee J-Y. Hypocholesterolemic effect of Nostoc commune var. sphaeroides Kützing, an edible blue-green alga. European Journal of Nutrition 2009;48:387-94.
24. Ku CS, Kim B, Pham TX, Yang Y, Weller CL, Carr TP, Park Y-K, Lee J-Y. Hypolipidemic Effect of a Blue-Green Alga (Nostoc commune) Is Attributed to Its Nonlipid Fraction by Decreasing Intestinal Cholesterol Absorption in C57BL/6J Mice. Journal of Medicinal Food 2015;18:1214-22.
25. Yang Y, Bae M, Park Y-K, Lee Y, Pham TX, Rudraiah S, Manautou J, Koo SI, Lee J-Y. Histone deacetylase 9 plays a role in the antifibrogenic effect of astaxanthin in hepatic stellate cells. The Journal of Nutritional Biochemistry 2017;40:172-77.
26. Gylling H, Plat J, Turley S, Ginsberg HN, Ellegård L, Jessup W, Jones PJ, Uutjohann D, Maerz W, Masana L, Silbernagel G, Staels B, Borén J, Catapano AL, De Backer G, Deanfield J, Descamps OS, Kovanen PT, Riccardi G, Tokgözoglu L, Chapman MJ. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014;232:346-60.
27. McNamara DJ. Dietary cholesterol and atherosclerosis. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 2000;1529:310-20.
28. McNamara JD. The Fifty Year Rehabilitation of the Egg. Nutrients 2015;7.
29. Berger S, Raman G, Vishwanathan R, Jacques PF, Johnson EI. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. The American Journal of Clinical Nutrition 2015;102:276-94.
30. Lecerf J-M, de Lorgeril M. Dietary cholesterol: from physiology to cardiovascular risk. British Journal of Nutrition 2011;106:6-14.
31. Feingold KR, Grunfeld C. Cholesterol Lowering Drugs. 2016.
32. Altmann SW, Davis HR, Yao X, Laverty M, Compton DS, Zhu L-j, Crona JH, Caplen MA, Hoos LM, Tetzloff G. The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 2002;1580:77-93.
33. Goncalves A, Gontero B, Nowicki M, Margier M, Masset G, Amiot M-J, Rebolu E. Micellar lipid composition affects micelle interaction with class B scavenger receptor extracellular loops. Journal of Lipid Research 2015;56:1123-33.
34. Betters JL, Yu L. NPC1L1 and cholesterol transport. FEBS letters 2010;584:2740-47.
35. Homan R, Hameleleh KE. Phospholipase A2 relieves phosphatidylcholine inhibition of micellar cholesterol absorption and transport by human intestinal cell line Caco-2. Journal of Lipid Research 1998;39:1197-209.
36. Richmond BL, Boileau AC, Zheng S, Huggins KW, Granholm NA, Tso P, Hui DY. Compensatory phospholipid digestion is required for cholesterol absorption in pancreatic phospholipase A<sub>2</sub>-Deficient mice. Gastroenterology;120:1193-202.
37. Miller CA, Corbin KD, da Costa K-A, Zhang S, Zhao X, Galanko JA, Blevins T, Bennett BJ, O’Connor A, Zeisel SH. Effect of egg ingestion on trimethylamine-N-oxide production in humans: a randomized, controlled, dose-response study. The American journal of clinical nutrition 2014;100:778-86.